Hypercholesteremia Clinical Trial
— ROYAL-1Official title:
A 12-Week, Phase 2 Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Gemcabene in Subjects With Hypercholesterolemia Not Adequately Controlled on High-Intensity or Moderate-Intensity Stable Statin Therapy
NCT number | NCT02634151 |
Other study ID # | GEM-301 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | November 2016 |
Est. completion date | August 2017 |
Verified date | June 2020 |
Source | NeuroBo Pharmaceuticals Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study was to assess the efficacy, safety, and tolerability of multiple doses of gemcabene 600 mg QD compared to placebo in patients with hypercholesterolemia not adequately controlled on high-intensity or moderate-intensity stable statin therapy. Patients with HeFH, ASCVD, or otherwise uncontrolled, may be included with baseline LDL-C value ≥ 100 mg/dL. Subjects were randomized 1:1 to gemcabene 600 mg once daily (QD) or placebo.
Status | Completed |
Enrollment | 105 |
Est. completion date | August 2017 |
Est. primary completion date | June 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
1. Provision of written and signed informed consent (by subject or legal guardian) prior
to any study-specific procedures; 2. Male or female (neither pregnant or lactating) = 18 years of age at the time of consent; 3. Currently on a stable, low-fat, low-cholesterol diet in combination with allowed statin doses as described in Table 1, with or without ezetimibe 10 mg QD for at least 12 weeks prior to the Screening Visit; 4. Fasting LDL-C value = 100 mg/dL (2.59 mmol/L) at the Screening Visit; 5. Physical examination, including vital signs, that is within normal limits or clinically acceptable to the Investigator; 6. Weight = 50 kg; with a body mass index (BMI) = 45 kg/m2 7. Subjects with Type 2 diabetes who take anti-hyperglycemic agents must be on a stable regimen for at least 3 months, with no planned changes in medications for the study duration. Exclusion Criteria 1. Abnormal liver function test at the Pre-Screening or Screening Visit (AST or ALT) > 2x ULN (upper limit of normal), total bilirubin > 1.5x ULN, or alkaline phosphate > 2x ULN based on appropriate age and gender normal values. Subjects with bilirubin > 1.5x ULN and a history of Gilbert's syndrome may be included; reflexive direct bilirubin testing will be used to confirm Gilbert's syndrome; 2. Moderate (Grade B) or severe (Grade C) chronic hepatic impairment according to the Child-Pugh classification; 3. Active liver disease (e.g. cirrhosis, alcoholic liver disease, hepatitis B, hepatitis C, autoimmune hepatitis, liver failure, liver cancer), history of liver transplant, known diagnosis of HIV or AIDS; 4. Triglyceride value = 500 mg/dL at the Pre-Screening Visit or the Screening Visit; 5. Moderate to severe renal insufficiency define as an estimated GFR < 60mL/min/1.73m (calculated using the Chronic Kidney Disease Epidemiology Collaboration equation) at the Pre-Screening Visit or Screening Visit; 6. Abnormal urinalysis (proteinuria greater than trace or any male or non-menstruating female with greater than trace hematuria) confirmed by reflexive urine protein:creatinine ration testing; 7. Uncontrolled thyroid disease; hyperthyroidism or hypothyroidism as defined by thyroid stimulating hormone (TSH) below the lower limit of normal or > 1.5x ULN, respectively, based on results from the Pre-Screening Visit or the Screening Visit. If controlled, treatment should be stable for at least 3 months prior to Screening; 8. Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus (hemoglobin A1c value > 8.5% based on results from the Pre-Screening or Screening Visit, or taking a thiazolidinedione (i.e. pioglitazone or rosiglitazone); 9. New York Heart Association Class III or IV heart failure; 10. Myocardial infarction, severe or unstable angina pectoris, coronary angioplasty, coronary artery bypass graft, or other major cardiovascular events resulting in hospitalization within 3 months of the Screening Visit. Subjects with adequately treated stable angina, per Investigator assessment, may be included; 11. Uncontrolled cardiac arrhythmia or prolonged QT on the Screening Visit or Day 1 prior to dosing ECG (QTcF > 450 msec for men and > 470 msec for women) or known family history of prolonged QT or unexplained sudden cardiac death; 12. Uncontrolled hypertension, defined as sitting systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg, and confirmed by repeat measurement; 13. Currently receiving cancer treatments or, in the Investigator's opinion, at risk of relapse for recent cancer; 14. Inadequate wash-out of a PCSK9 inhibitor (8 weeks prior to the Screening Visit), a fibrate lipid-regulating agent (6 weeks prior to the Screening Visit), niacins (4 weeks prior to the Screening Visit), or other lipid-regulating therapies such as bile acid sequestrants (4 weeks prior to the Screening Visit); 15. Hypersensitivity to or a history of significant adverse reactions to any fibrate lipid-regulating agent; 16. Use of any excluded medications or supplements (e.g. potent cytochrome P450 [CYP] 3A4 inhibitors as described in Appendix D; 17. History of drug or alcohol abuse within the past year or inability to comply with protocol requirements, including subjects restrictions (see Section 5.6.3); 18. Previously treated with gemcabene (CI-1027), participation in another clinical study of an investigational agent or device concurrently or within 1 month prior the Screening Visit, or use of an investigational agent within 1 month or 5 half-lives (if known), whichever is longer, prior to the Screening Visit; 19. Any other finding which, in the opinion of the Investigator, would compromise the subject's safety or participation in the study. |
Country | Name | City | State |
---|---|---|---|
United States | Atlantic Clinical Research Collaborative- Cardiology | Atlantis | Florida |
United States | Westside Medical Associates of Los Angeles | Beverly Hills | California |
United States | Central Research Associates, Inc. | Birmingham | Alabama |
United States | Excel Medical Clinical Trials | Boca Raton | Florida |
United States | Sentral Clinical Research Services | Cincinnati | Ohio |
United States | Sterling Research Group, Ltd. | Cincinnati | Ohio |
United States | Sterling Research Group, Ltd. | Cincinnati | Ohio |
United States | Evanston Premier Healthcare Research, LLC | Evanston | Illinois |
United States | Associates in Medicine | Houston | Texas |
United States | National Research Institute | Huntington Park | California |
United States | Midwest Institute for Clinical Research | Indianapolis | Indiana |
United States | Jacksonville Center for Clinical Research | Jacksonville | Florida |
United States | Health Awareness, Inc. | Jupiter | Florida |
United States | Green and Seidner Family Practice Associates | Lansdale | Pennsylvania |
United States | National Research Institute | Los Angeles | California |
United States | L-MARC | Louisville | Kentucky |
United States | Meridien Research, Inc. | Maitland | Florida |
United States | Mid-Hudson Medical Research | New Windsor | New York |
United States | Progressive Medical Research | Port Orange | Florida |
United States | National Research Institute | Richmond | Virginia |
United States | Rochester Clinical Research, Inc. | Rochester | New York |
United States | Diagnostics Research Grup | San Antonio | Texas |
United States | Sugar Lakes Family Practice | Sugar Land | Texas |
United States | Varkey Medical | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
NeuroBo Pharmaceuticals Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent Change From Baseline in LDL-C at Week 12 | Baseline, Week 12 | ||
Secondary | Percent Change From Baseline in LDL-C by Statin Intensity Stratum | The intensity of statin therapy was determined based on the statin dose.Participants were categorized as high intensity & moderate intensity based on their statin doses. | Baseline, Week 12 | |
Secondary | Change From Baseline in LDL-C | Baseline, Weeks 2, 4, 8, 12 and average of weeks 8 and 12 | ||
Secondary | Percent Change From Baseline in LDL-C | Baseline, average of weeks 8 and 12 | ||
Secondary | Percent Change From Baseline in Non-HDL-C | Baseline, Weeks 2, 4, 8 and 12 | ||
Secondary | Change From Baseline in Non-HDL-C | Baseline, Weeks 2, 4, 8 and 12 | ||
Secondary | Percent Change From Baseline in TC | Baseline, Weeks 2, 4, 8 and 12 | ||
Secondary | Change From Baseline in TC | Baseline, Weeks 2, 4, 8 and 12 | ||
Secondary | Percent Change From Baseline in TG | Baseline, Weeks 2, 4, 8 and 12 | ||
Secondary | Change From Baseline in TG | Baseline, Weeks 2, 4, 8 and 12 | ||
Secondary | Percent Change From Baseline in VLDL-C | Baseline, Weeks 2, 4, 8 and 12 | ||
Secondary | Change From Baseline in VLDL-C | Baseline, Weeks 2, 4, 8 and 12 | ||
Secondary | Percent Change From Baseline in HDL-C | Baseline, Weeks 2, 4, 8 and 12 | ||
Secondary | Change From Baseline in HDL-C | Baseline, Weeks 2, 4, 8 and 12 | ||
Secondary | Number of Participants Achieving LDL-C Reduction of =10% | Weeks 4, 8 and 12 | ||
Secondary | Number of Participants Achieving LDL-C Reduction of =15% | Weeks 4, 8 and 12 | ||
Secondary | Number of Participants Achieving LDL-C Reduction of =20% | Weeks 4, 8 and 12 | ||
Secondary | Number of Participants Achieving an LDL-C Value <100 mg/dL (2.59 mmol/L) | Weeks 4, 8 and 12 | ||
Secondary | Percent Change From Baseline in Apolipoprotein B | Baseline, Weeks 4, 8 and 12 | ||
Secondary | Change From Baseline in Apolipoprotein B | Baseline, Weeks 4, 8 and 12 | ||
Secondary | Percent Change From Baseline in Apolipoprotein A-I | Baseline, Weeks 4, 8 and 12 | ||
Secondary | Change From Baseline in Apolipoprotein A-I | Baseline, Weeks 4, 8 and 12 | ||
Secondary | Percent Change From Baseline in Apolipoprotein A-II | Baseline, Weeks 4, 8 and 12 | ||
Secondary | Change From Baseline in Apolipoprotein A-II | Baseline, Weeks 4, 8 and 12 | ||
Secondary | Percent Change From Baseline in Apolipoprotein C-II | Baseline, Weeks 4, 8 and 12 | ||
Secondary | Change From Baseline in Apolipoprotein C-II | Baseline, Weeks 4, 8 and 12 | ||
Secondary | Percent Change From Baseline in Apolipoprotein C-III | Baseline, Weeks 4, 8 and 12 | ||
Secondary | Change From Baseline in Apolipoprotein C-III | Baseline, Weeks 4, 8 and 12 | ||
Secondary | Percent Change From Baseline in Apolipoprotein E | Baseline, Weeks 4, 8 and 12 | ||
Secondary | Change From Baseline in Apolipoprotein E | Baseline, Weeks 4, 8 and 12 | ||
Secondary | Percent Change From Baseline in Lipoprotein(a) | Baseline, Weeks 4, 8 and 12 | ||
Secondary | Change From Baseline in Lipoprotein(a) | Baseline, Weeks 4, 8 and 12 | ||
Secondary | Percent Change From Baseline in High-sensitivity C-reactive Protein | Baseline, Week 12 | ||
Secondary | Change From Baseline in High-sensitivity C-reactive Protein | Baseline, Week 12 | ||
Secondary | Percent Change From Baseline in Fibrinogen | Baseline, Week 12 | ||
Secondary | Change From Baseline in Fibrinogen | Baseline, Week 12 | ||
Secondary | Percent Change From Baseline in Serum Amyloid A | Baseline, Week 12 | ||
Secondary | Change From Baseline in Serum Amyloid A | Baseline, Week 12 | ||
Secondary | Percent Change From Baseline in Adiponectin | Baseline, Week 12 | ||
Secondary | Change From Baseline in Adiponectin | Baseline, Week 12 | ||
Secondary | Change From Baseline in Framingham Risk Score | Framingham Risk Score was an estimate of a participant's 10-year risk of developing cardiovascular disease which was computed using sex-specific algorithms based on total point score (range less than negative 3 [best] to greater than or equal to 14 [worst] for men; less than or equal to negative 2 [best] and greater than or equal to 17 [worst] for women) : which was derived of participant's age, systolic blood pressure , smoking status, TC, HDL-C, treatment for hypertension, and diabetes status. Reported score is a percentage. Change from baseline calculated as mean at week 12 minus mean at baseline. Negative scores indicate less risk of developing cardiovascular disease. | Baseline, Week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05164185 -
The Effect of Remote Ischemic Conditioning in Patients With Hypercholesterolemia
|
N/A | |
Completed |
NCT00329160 -
Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease
|
Phase 4 | |
Completed |
NCT02587416 -
Effect of Gemcabene on the Pharmacokinetics of Atorvastatin in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00153738 -
Phytosterol Supplementation and Cardiovascular Risk
|
N/A | |
Completed |
NCT02722408 -
Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)
|
Phase 2 | |
Completed |
NCT00239330 -
Direct Statin Comparison of LDL-C Values: an Evaluation of Rosuvastatin Therapy
|
Phase 3 | |
Recruiting |
NCT01890889 -
Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health
|
N/A | |
Completed |
NCT00376584 -
Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)
|
Phase 3 | |
Completed |
NCT01477944 -
Pattern of Statins Use in Catalonia
|
N/A | |
Completed |
NCT00688454 -
C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients
|
N/A | |
Completed |
NCT00347217 -
Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event
|
Phase 4 | |
Completed |
NCT01354327 -
Effects of Limicol on LDL-cholesterol
|
N/A | |
Completed |
NCT03634436 -
The PK/PD Study of A Single Subcutaneous Injection of SHR-1209 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT00225589 -
A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)
|
Phase 3 | |
Completed |
NCT02850224 -
Pediatric Preventative Health Screenings - Obesity and Family-Centered Outcomes
|
N/A | |
Completed |
NCT00408382 -
Lipitor Phase 4 Clinical Trial in Hypercholesteremia Patients With Yellow Coronary Plaque
|
Phase 4 |